Actinium Shares Are Trading Higher After Positive Data From Acute Myeloid Leukemia Trial

  • Actinium Pharmaceuticals Inc ATNM announced positive topline results from the pivotal Phase 3 trial for its lead product candidate Iomab-B, a first-in-class targeted radiotherapy.
  • The SIERRA trial was conducted in patients 55 or older with active disease (relapsed or refractory Acute Myeloid Leukemia). 
  • Related: With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium.
  • The SIERRA trial compared Iomab-B as a conditioning (preparing) regimen before a Bone Marrow Transplant (BMT) versus a control arm which allowed all current means of conventional care with the intent to transplant these patients. 
  • The SIERRA trial met its primary endpoint of durable complete remission (dCR) of 6 months post initial remission after a BMT in the Iomab-B arm compared to the conventional care arm demonstrating statistical significance.
  • "We look forward to sharing additional clinical data from the SIERRA trial by year-end," commented Sandesh Seth, Actinium's Chairman & CEO.
  • In previously highlighted data, a 100% BMT and engraftment rate for patients receiving a therapeutic dose of Iomab-B was observed compared to 18% of patients receiving a physician's choice of salvage therapy on the control arm.
  • Price Action: ATNM shares are up 24.82% at $12.15 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!